We are live on ! Find out more
P

Pfizer Portfolio holdings

AUM $239M
1-Year Est. Return 232.47%
This Fund
S&P 500
This Quarter Est. Return
+29.23%
1 Year Est. Return
+232.47%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$239M
AUM Growth
+$2.31M
Cap. Flow
-$14.1M
Cap. Flow %
-5.89%
Top 10 Hldgs %
96.23%
Holding
19
New
1
Increased
–
Reduced
5
Closed
1

Top Buys

Rank Stock Value
1
AGMB
AgomAb Therapeutics NV
AGMB
+$1.06M

Top Sells

Rank Stock Value
1
ORIC icon
Oric Pharmaceuticals
ORIC
+$6.77M
2
CELC icon
Celcuity
CELC
+$5.86M
3
QTTB icon
Q32 Bio
QTTB
+$837K
4
ANTX icon
AN2 Therapeutics
ANTX
+$815K
5
ZURA icon
Zura Bio
ZURA
+$792K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORIC icon
1
Oric Pharmaceuticals
ORIC
$1.11B
$57.7M 24.14%
4,780,401
-595,943
-11% -$6.77M
ALLO icon
2
Allogene Therapeutics
ALLO
$618M
$49.8M 20.85%
22,032,040
– –
ARVN icon
3
Arvinas
ARVN
$518M
$34.9M 14.63%
3,457,815
– –
CELC icon
4
Celcuity
CELC
$4.31B
$31.3M 13.13%
295,652
-53,754
-15% -$5.86M
ZURA icon
5
Zura Bio
ZURA
$499M
$16.8M 7.05%
2,838,913
-131,109
-4% -$792K
WVE icon
6
Wave Life Sciences
WVE
$1.09B
$11.9M 5%
1,875,000
– –
PYXS icon
7
Pyxis Oncology
PYXS
$141M
$9.21M 3.86%
7,032,770
– –
CRBU icon
8
Caribou Biosciences
CRBU
$165M
$8.35M 3.5%
4,690,431
– –
SPRO icon
9
Spero Therapeutics
SPRO
$90.9M
$5.5M 2.31%
2,362,348
– –
BHVN icon
10
Biohaven
BHVN
$2.13B
$4.23M 1.77%
505,645
– –
CRDF icon
11
Cardiff Oncology
CRDF
$59.8M
$3.74M 1.57%
2,411,575
– –
ZNTL icon
12
Zentalis Pharmaceuticals
ZNTL
$325M
$2M 0.84%
953,834
– –
NXTC icon
13
NextCure
NXTC
$25.1M
$1.54M 0.64%
153,354
-4,292
-3% -$52.4K
AGMB
14
AgomAb Therapeutics NV
AGMB
$607M
$814K 0.34%
+75,000
New +$1.06M
QTTB icon
15
Q32 Bio
QTTB
$258M
$737K 0.31%
101,618
-176,159
-63% -$837K
BOLT icon
16
Bolt Biotherapeutics
BOLT
$8.05M
$137K 0.06%
31,305
– –
DNA icon
17
Ginkgo Bioworks
DNA
$542M
$17.4K 0.01%
2,928
– –
SENS icon
18
Senseonics Holdings Inc
SENS
$268M
$14.2K 0.01%
2,171
– –
ANTX icon
19
AN2 Therapeutics
ANTX
$168M
– –
-715,295
Closed -$815K

Similar funds

DCC
Dow Chemical Company Midland, Michigan $239M AUM 13.16% 1-Year Est. Return
OCERS
Orange County Employees Retirement System Santa Ana, California $239M AUM
CWMGP
Capstone Wealth Management Group (Pennsylvania) Clarks Green, Pennsylvania $239M AUM 18.48% 1-Year Est. Return
WWA
Wealth Watch Advisors Englewood, Colorado $239M AUM 21.17% 1-Year Est. Return
MFC
Mechanics Financial Corp Mansfield, Ohio $239M AUM 25.61% 1-Year Est. Return
RCM
Robinson Capital Management Grosse Pointe Farms, Michigan $239M AUM 0.62% 1-Year Est. Return
TGIA
Torrey Growth & Income Advisors Del Mar, California $239M AUM
GCA
Genesee Capital Advisors Auburn, New York $239M AUM 20.45% 1-Year Est. Return

Pfizer's Q1 2026 Portfolio in Review

As of Q1 2026, Pfizer held 19 positions worth $239M, up 0.98% from $236M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Pfizer withdrew a net $14.1M in Q1 2026, closing 1 position and reducing 5 holdings. Its most notable exit was AN2 Therapeutics, an estimated $815K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Pfizer opened a new position in AgomAb Therapeutics NV worth $814K.

  • Pfizer's largest Q1 2026 buy was AgomAb Therapeutics NV: 75,000 shares worth $814K.
  • Pfizer's biggest Q1 2026 reduction was Oric Pharmaceuticals, cutting an estimated $6.77M.
  • Pfizer fully exited AN2 Therapeutics in Q1 2026, selling an estimated $815K.
  • Pfizer's ten largest holdings make up 96% of its $239M portfolio in Q1 2026.
  • Pfizer opened 1 new position and closed 1 in Q1 2026.
  • Pfizer's portfolio value rose 0.98% quarter-over-quarter to $239M.

Based on Pfizer's 13F filing for Q1 2026, filed 12 May 2026.